These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 35383113)

  • 1. Characterization of the treatment-naive immune microenvironment in melanoma with
    Wang M; Zadeh S; Pizzolla A; Thia K; Gyorki DE; McArthur GA; Scolyer RA; Long G; Wilmott JS; Andrews MC; Au-Yeung G; Weppler A; Sandhu S; Trapani JA; Davis MJ; Neeson PJ
    J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35383113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted Therapy Given after Anti-PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor Immunity.
    Phadke MS; Chen Z; Li J; Mohamed E; Davies MA; Smalley I; Duckett DR; Palve V; Czerniecki BJ; Forsyth PA; Noyes D; Adeegbe DO; Eroglu Z; Nguyen KT; Tsai KY; Rix U; Burd CE; Chen YA; Rodriguez PC; Smalley KSM
    Cancer Immunol Res; 2021 May; 9(5):554-567. PubMed ID: 33653716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Based on scRNA-seq and bulk RNA-seq to establish tumor immune microenvironment-associated signature of skin melanoma and predict immunotherapy response.
    Li S; Zhao J; Wang G; Yao Q; Leng Z; Liu Q; Jiang J; Wang W
    Arch Dermatol Res; 2024 May; 316(6):262. PubMed ID: 38795156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma.
    Ferrari de Andrade L; Ngiow SF; Stannard K; Rusakiewicz S; Kalimutho M; Khanna KK; Tey SK; Takeda K; Zitvogel L; Martinet L; Smyth MJ
    Cancer Res; 2014 Dec; 74(24):7298-308. PubMed ID: 25351955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Immune Microenvironment Comparation Study between EGFR Mutant and EGFR Wild Type Lung Adenocarcinoma Patients Based on TCGA Database].
    Zhu G; Li Y; Shi R; Xu S; Zhang Z; Cao P; Chen C; Liu H; Chen J
    Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):236-244. PubMed ID: 33910272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Features of Resected Melanoma Brain Metastases, Clinical Outcomes, and Responses to Immunotherapy.
    Vasudevan HN; Delley C; Chen WC; Mirchia K; Pan S; Shukla P; Aabedi AA; Nguyen MP; Morshed RA; Young JS; Boreta L; Fogh SE; Nakamura JL; Theodosopoulos PV; Phillips J; Hervey-Jumper SL; Daras M; Pike L; Aghi MK; Tsai K; Raleigh DR; Braunstein SE; Abate AR
    JAMA Netw Open; 2023 Aug; 6(8):e2329186. PubMed ID: 37589977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.
    Ziogas DC; Konstantinou F; Bouros S; Theochari M; Gogas H
    Am J Clin Dermatol; 2021 May; 22(3):301-314. PubMed ID: 33765322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma.
    Falkenius J; Johansson H; Tuominen R; Frostvik Stolt M; Hansson J; Egyhazi Brage S
    BMC Cancer; 2017 Aug; 17(1):584. PubMed ID: 28851300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis.
    Erkes DA; Cai W; Sanchez IM; Purwin TJ; Rogers C; Field CO; Berger AC; Hartsough EJ; Rodeck U; Alnemri ES; Aplin AE
    Cancer Discov; 2020 Feb; 10(2):254-269. PubMed ID: 31796433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic Strategies in BRAF V600 Wild-Type Cutaneous Melanoma.
    Haugh A; Daud AI
    Am J Clin Dermatol; 2024 May; 25(3):407-419. PubMed ID: 38329690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
    Chen G; McQuade JL; Panka DJ; Hudgens CW; Amin-Mansour A; Mu XJ; Bahl S; Jané-Valbuena J; Wani KM; Reuben A; Creasy CA; Jiang H; Cooper ZA; Roszik J; Bassett RL; Joon AY; Simpson LM; Mouton RD; Glitza IC; Patel SP; Hwu WJ; Amaria RN; Diab A; Hwu P; Lazar AJ; Wargo JA; Garraway LA; Tetzlaff MT; Sullivan RJ; Kim KB; Davies MA
    JAMA Oncol; 2016 Aug; 2(8):1056-64. PubMed ID: 27124486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Immunogenic Cell Death-Related Gene Signature Reflects Immune Landscape and Predicts Prognosis in Melanoma Independently of BRAF V600E Status.
    Chen L; Wen Y; Xiong J; Chen Y; Chen CB
    Biomed Res Int; 2023; 2023():1189022. PubMed ID: 36704723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Type I-polarized BRAF-pulsed dendritic cells induce antigen-specific CD8+ T cells that impact BRAF-mutant murine melanoma.
    Cintolo JA; Datta J; Xu S; Gupta M; Somasundaram R; Czerniecki BJ
    Melanoma Res; 2016 Feb; 26(1):1-11. PubMed ID: 26451873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.
    Kim KB; Kefford R; Pavlick AC; Infante JR; Ribas A; Sosman JA; Fecher LA; Millward M; McArthur GA; Hwu P; Gonzalez R; Ott PA; Long GV; Gardner OS; Ouellet D; Xu Y; DeMarini DJ; Le NT; Patel K; Lewis KD
    J Clin Oncol; 2013 Feb; 31(4):482-9. PubMed ID: 23248257
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Liu J; Lin J; Wang X; Zheng X; Gao X; Huang Y; Chen G; Xiong J; Lan B; Chen C; Si L; Chen Y
    Front Immunol; 2022; 13():725679. PubMed ID: 35844619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-line pembrolizumab versus dabrafenib/trametinib treatment for BRAF V600-mutant advanced melanoma.
    Kim CG; Kim M; Hwang J; Kim ST; Jung M; Kim KH; Kim KH; Chang JS; Koom WS; Roh MR; Chung KY; Kim TM; Kim SK; Lee J; Shin SJ
    J Am Acad Dermatol; 2022 Nov; 87(5):989-996. PubMed ID: 36068115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with
    Tawbi HA; Robert C; Brase JC; Gusenleitner D; Gasal E; Garrett J; Savchenko A; Görgün G; Flaherty KT; Ribas A; Dummer R; Schadendorf D; Long GV; Nathan PD; Ascierto PA
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35728875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FOXP3+ T regulatory lymphocytes in primary melanoma are associated with BRAF mutation but not with response to BRAF inhibitor.
    Leslie C; Bowyer SE; White A; Grieu-Iacopetta F; Trevenen M; Iacopetta B; Amanuel B; Millward M
    Pathology; 2015 Oct; 47(6):557-63. PubMed ID: 26308130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor Activity of BRAF Inhibitor and IFNα Combination in BRAF-Mutant Melanoma.
    Sabbatino F; Wang Y; Scognamiglio G; Favoino E; Feldman SA; Villani V; Flaherty KT; Nota S; Giannarelli D; Simeone E; Anniciello AM; Palmieri G; Pepe S; Botti G; Ascierto PA; Ferrone CR; Ferrone S
    J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26851802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Skin immunization for effective treatment of multifocal melanoma refractory to PD1 blockade and Braf inhibitors.
    Hao X; Falo Iii LD; Chen G; Zhang J; Carey CD; Storkus WJ; Falo LD; You Z
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33408093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.